Literature DB >> 7518791

Modulation of the immune response with T-cell epitopes: the ultimate goal for specific immunotherapy of autoimmune disease.

P J Fairchild1, C J Thorpe, P J Travers, D C Wraith.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7518791      PMCID： PMC1422373     

Source DB:  PubMed          Journal:  Immunology        ISSN： 0019-2805            Impact factor:   7.397


× No keyword cloud information.
  105 in total

1.  Irreversible association of peptides with class II MHC molecules in living cells.

Authors:  A Lanzavecchia; P A Reid; C Watts
Journal:  Nature       Date:  1992-05-21       Impact factor: 49.962

2.  CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones.

Authors:  F A Harding; J G McArthur; J A Gross; D H Raulet; J P Allison
Journal:  Nature       Date:  1992-04-16       Impact factor: 49.962

Review 3.  How MHC class II molecules work: peptide-dependent completion of protein folding.

Authors:  S Sadegh-Nasseri; R N Germain
Journal:  Immunol Today       Date:  1992-02

4.  Antigen recognition in autoimmune encephalomyelitis and the potential for peptide-mediated immunotherapy.

Authors:  D C Wraith; D E Smilek; D J Mitchell; L Steinman; H O McDevitt
Journal:  Cell       Date:  1989-10-20       Impact factor: 41.582

5.  Response of a protein structure to cavity-creating mutations and its relation to the hydrophobic effect.

Authors:  A E Eriksson; W A Baase; X J Zhang; D W Heinz; M Blaber; E P Baldwin; B W Matthews
Journal:  Science       Date:  1992-01-10       Impact factor: 47.728

6.  Effect of T-cell receptor antagonism on interaction between T cells and antigen-presenting cells and on T-cell signaling events.

Authors:  J Ruppert; J Alexander; K Snoke; M Coggeshall; E Herbert; D McKenzie; H M Grey; A Sette
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

7.  Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen.

Authors:  P V Lehmann; T Forsthuber; A Miller; E E Sercarz
Journal:  Nature       Date:  1992-07-09       Impact factor: 49.962

8.  Effects of oral administration of type II collagen on rheumatoid arthritis.

Authors:  D E Trentham; R A Dynesius-Trentham; E J Orav; D Combitchi; C Lorenzo; K L Sewell; D A Hafler; H L Weiner
Journal:  Science       Date:  1993-09-24       Impact factor: 47.728

9.  Selective immunosuppression by administration of major histocompatibility complex (MHC) class II-binding peptides. I. Evidence for in vivo MHC blockade preventing T cell activation.

Authors:  J C Guéry; A Sette; J Leighton; A Dragomir; L Adorini
Journal:  J Exp Med       Date:  1992-05-01       Impact factor: 14.307

10.  Self-peptide released from class II HLA-DR1 exhibits a hydrophobic two-residue contact motif.

Authors:  H Kropshofer; H Max; C A Müller; F Hesse; S Stevanovic; G Jung; H Kalbacher
Journal:  J Exp Med       Date:  1992-06-01       Impact factor: 14.307
View more
  6 in total

1.  Fine mapping of T-cell determinants of bovine beta-lactoglobulin.

Authors:  M Totsuka; A Ametani; S Kaminogawa
Journal:  Cytotechnology       Date:  1997       Impact factor: 2.058

2.  3rd International Symposium on the Immunotherapy of the Rheumatic Diseases. 10-14 May 1995, Cyprus. Abstracts.

Authors: 
Journal:  Ann Rheum Dis       Date:  1995-09       Impact factor: 19.103

3.  Complexities of applying nasal tolerance induction as a therapy for ongoing relapsing experimental autoimmune encephalomyelitis (EAE) in DA rats.

Authors:  X F Bai; H L Li; F D Shi; J Q Liu; B G Xiao; P H Van der Meide; H Link
Journal:  Clin Exp Immunol       Date:  1998-01       Impact factor: 4.330

4.  Peptide-induced nasal tolerance for a mycobacterial heat shock protein 60 T cell epitope in rats suppresses both adjuvant arthritis and nonmicrobially induced experimental arthritis.

Authors:  B J Prakken; R van der Zee; S M Anderton; P J van Kooten; W Kuis; W van Eden
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

5.  Negative selection during the peripheral immune response to antigen.

Authors:  S M Anderton; C G Radu; P A Lowrey; E S Ward; D C Wraith
Journal:  J Exp Med       Date:  2001-01-01       Impact factor: 14.307

Review 6.  Design of peptide immunotherapies for MHC Class-II-associated autoimmune disorders.

Authors:  Masha Fridkis-Hareli
Journal:  Clin Dev Immunol       Date:  2013-11-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.